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BACKGROUND
Hydroxychloroquine and chloroquine have been proposed as treatments for coro-
navirus disease 2019 (Covid-19) on the basis of in vitro activity and data from 
uncontrolled studies and small, randomized trials.
METHODS
In this randomized, controlled, open-label platform trial comparing a range of 
possible treatments with usual care in patients hospitalized with Covid-19, we 
randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive 
usual care. The primary outcome was 28-day mortality.
RESULTS
The enrollment of patients in the hydroxychloroquine group was closed on June 5, 
2020, after an interim analysis determined that there was a lack of efficacy. Death 
within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group 
and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence inter-
val [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified 
subgroups of patients. The results suggest that patients in the hydroxychloroquine 
group were less likely to be discharged from the hospital alive within 28 days than 
those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 
0.98). Among the patients who were not undergoing mechanical ventilation at 
baseline, those in the hydroxychloroquine group had a higher frequency of invasive 
mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 
1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) 
but no difference in the incidence of new major cardiac arrhythmia among the 
patients who received hydroxychloroquine.
CONCLUSIONS
Among patients hospitalized with Covid-19, those who received hydroxychloro-
quine did not have a lower incidence of death at 28 days than those who received 
usual care. (Funded by UK Research and Innovation and National Institute for 
Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; 
ClinicalTrials.gov number, NCT04381936.)
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (Covid-19), emerged 
in China in late 2019 from a zoonotic source.1 
The majority of Covid-19 infections are either 
asymptomatic or result in only mild disease. 
However, in a substantial proportion of infected 
persons, the infection leads to a respiratory ill-
ness requiring hospital care,2 which can progress 
to critical illness with hypoxemic respiratory fail-
ure and lead to prolonged ventilatory support.3-6 
Among the patients with Covid-19 who have been 
admitted to hospitals in the United Kingdom, 
the case fatality rate is approximately 30%.7
Hydroxychloroquine and chloroquine, two 
4-aminoquinoline drugs that were developed 
more than 70 years ago and have been used to 
treat malaria and rheumatologic conditions, have 
been proposed as treatments for Covid-19. Chloro-
quine has been shown to have in vitro activity 
against a variety of viruses, including SARS-CoV-2 
and the related SARS-CoV-1.8-13 The exact mecha-
nism of antiviral action is uncertain, but these 
drugs increase the pH of endosomes that the 
virus uses for cell entry and also interfere with 
the glycosylation of angiotensin-converting–
enzyme 2 (ACE2), which is the cellular receptor 
of SARS-CoV, and of associated gangliosides.10,14 
The 4-aminoquinoline levels that are required to 
inhibit SARS-CoV-2 replication in vitro are higher 
than the free plasma levels that have been ob-
served in the prevention and treatment of ma-
laria.15 These drugs generally have an acceptable 
side-effect profile and are inexpensive and wide-
ly available. After oral administration, they are 
rapidly absorbed, even in severely ill patients. 
Therapeutic hydroxychloroquine levels could be 
expected to be reached in human lung tissue 
shortly after an initial loading dose.
In small preclinical studies of SARS-CoV-2 
infection in animals, prophylaxis or treatment 
with hydroxychloroquine had no beneficial ef-
fect on clinical disease or viral replication.16 A 
clinical benefit and an antiviral effect from the 
administration of these drugs alone or in com-
bination with azithromycin in patients with 
Covid-19 have been reported in some observa-
tional studies17-21 but not in others.22-24 The re-
sults of a few small trials of hydroxychloroquine 
or chloroquine for the treatment of Covid-19 have 
been inconclusive, whereas one larger random-
ized, controlled trial involving patients who were 
hospitalized with mild-to-moderate Covid-19 
showed that hydroxychloroquine (at a dose of 
400 mg twice daily, with or without azithromy-
cin) did not improve clinical status at day 15, as 
compared with usual care.25-29 Here, as part of 
the controlled, open-label Randomized Evalua-
tion of Covid-19 Therapy (RECOVERY) trial, we 
report the results of a comparison between hy-
droxychloroquine and usual care involving pa-
tients hospitalized with Covid-19.
Me thods
Trial Design and Oversight
The RECOVERY trial is an investigator-initiated 
platform trial to evaluate the effects of potential 
treatments in patients hospitalized with Covid-19. 
The trial is being conducted at 176 hospitals in 
the United Kingdom. (Details are provided in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.) The investigators 
were assisted by the National Institute for Health 
Research Clinical Research Network, and the 
trial is coordinated by the Nuffield Department 
of Population Health at the University of Oxford, 
the trial sponsor. Although patients are no lon-
ger being enrolled in the hydroxychloroquine, 
dexamethasone, and lopinavir–ritonavir groups, 
the trial continues to study the effects of azithro-
mycin, tocilizumab, convalescent plasma, and 
REGN-COV2 (a combination of two monoclonal 
antibodies directed against the SARS-CoV-2 spike 
protein). Other treatments may be studied in the 
future. The hydroxychloroquine that was used in 
this phase of the trial was supplied by the U.K. 
National Health Service (NHS).
Hospitalized patients were eligible for the 
trial if they had clinically-suspected or laboratory-
confirmed SARS-CoV-2 infection and no medical 
history that might, in the opinion of the attend-
ing clinician, put patients at substantial risk if 
they were to participate in the trial. Initially, 
recruitment was limited to patients who were at 
least 18 years of age, but the age limit was re-
moved as of May 9, 2020.
Written informed consent was obtained from 
all the patients or from a legal representative if 
they were too unwell or unable to provide con-
sent. The trial was conducted in accordance with 
Good Clinical Practice guidelines of the Interna-
tional Conference on Harmonisation and was 
approved by the U.K. Medicines and Healthcare 
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Products Regulatory Agency (MHRA) and the 
Cambridge East Research Ethics Committee. 
The protocol with its statistical analysis plan are 
available at NEJM.org, with additional informa-
tion in the Supplementary Appendix and on the 
trial website at www . recoverytrial . net.
The initial version of the manuscript was 
drafted by the first and last authors, developed 
by the writing committee, and approved by all 
members of the trial steering committee. The 
funders had no role in the analysis of the data, 
in the preparation or approval of the manuscript, 
or in the decision to submit the manuscript for 
publication. The first and last members of the 
writing committee vouch for the completeness 
and accuracy of the data and for the fidelity of the 
trial to the protocol and statistical analysis plan.
Randomization and Treatment
We collected baseline data using a Web-based 
case-report form that included demographic 
data, level of respiratory support, major coexist-
ing illnesses, the suitability of the trial treat-
ment for a particular patient, and treatment 
availability at the trial site. Using a Web-based 
unstratified randomization method with the con-
cealment of trial group, we assigned patients to 
receive either the usual standard of care or the 
usual standard of care plus hydroxychloroquine 
or one of the other available treatments that were 
being evaluated. The number of patients who 
were assigned to receive usual care was twice the 
number who were assigned to any of the active 
treatments for which the patient was eligible 
(e.g., 2:1 ratio in favor of usual care if the patient 
was eligible for only one active treatment group, 
2:1:1 if the patient was eligible for two active 
treatments, etc.).
For some patients, hydroxychloroquine was 
unavailable at the hospital at the time of enroll-
ment or was considered by the managing physi-
cian to be either definitely indicated or definitely 
contraindicated. Patients with a known prolonged 
corrected QT interval on electrocardiography 
were ineligible to receive hydroxychloroquine. 
(Coadministration with medications that prolong 
the QT interval was not an absolute contraindi-
cation, but attending clinicians were advised to 
check the QT interval by performing electrocar-
diography.) These patients were excluded from 
entry in the randomized comparison between 
hydroxychloroquine and usual care.
In the hydroxychloroquine group, patients re-
ceived hydroxychloroquine sulfate (in the form 
of a 200-mg tablet containing a 155-mg base 
equivalent) in a loading dose of four tablets (total 
dose, 800 mg) at baseline and at 6 hours, which 
was followed by two tablets (total dose, 400 mg) 
starting at 12 hours after the initial dose and 
then every 12 hours for the next 9 days or until 
discharge, whichever occurred earlier (see the 
Supplementary Appendix).15 The assigned treat-
ment was prescribed by the attending clinician. 
The patients and local trial staff members were 
aware of the assigned trial groups.
Procedures
A single online follow-up form was to be com-
pleted by the local trial staff members when 
each trial patient was discharged, at 28 days af-
ter randomization, or at the time of death, which-
ever occurred first. Information was recorded 
regarding the adherence to the assigned treat-
ment, receipt of other treatments for Covid-19, 
duration of admission, receipt of respiratory 
support (with duration and type), receipt of renal 
dialysis or hemofiltration, and vital status (in-
cluding cause of death). Starting on May 12, 2020, 
extra information was recorded on the occur-
rence of new major cardiac arrhythmia. In addi-
tion, we obtained routine health care and regis-
try data that included information on vital status 
(with date and cause of death) and discharge 
from the hospital.
Outcome Measures
The primary outcome was all-cause mortality 
within 28 days after randomization; further 
analyses were specified at 6 months. Secondary 
outcomes were the time until discharge from the 
hospital and a composite of the initiation of in-
vasive mechanical ventilation including extracor-
poreal membrane oxygenation or death among 
patients who were not receiving invasive mechani-
cal ventilation at the time of randomization. 
Decisions to initiate invasive mechanical ventila-
tion were made by the attending clinicians, who 
were informed by guidance from NHS England 
and the National Institute for Health and Care 
Excellence. Subsidiary clinical outcomes included 
cause-specific mortality (which was recorded in 
all patients) and major cardiac arrhythmia (which 
was recorded in a subgroup of patients). All in-
formation presented in this report is based on a 
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on November 24, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;21 nejm.org November 19, 2020 2033
Hydroxychloroquine in Patients with Covid-19
data cutoff of September 21, 2020. Information 
regarding the primary outcome is complete for 
all the trial patients.
Statistical Analysis
For the primary outcome of 28-day mortality, we 
used the log-rank observed-minus-expected sta-
tistic and its variance both to test the null hy-
pothesis of equal survival curves and to calculate 
the one-step estimate of the average mortality 
rate ratio in the comparison between the hydroxy-
chloroquine group and the usual-care group. 
Kaplan–Meier survival curves were constructed 
to show cumulative mortality over the 28-day 
period. The same methods were used to analyze 
the time until hospital discharge, with censor-
ing of data on day 29 for patients who had died 
in the hospital. We used the Kaplan–Meier esti-
mates to calculate the median time until hospi-
tal discharge. For the prespecified composite 
secondary outcome of invasive mechanical venti-
lation or death within 28 days (among patients 
who had not been receiving invasive mechanical 
ventilation at randomization), the precise date of 
the initiation of invasive mechanical ventilation 
was not available, so the risk ratio was estimated 
instead. Estimates of the between-group differ-
ence in absolute risk were also calculated.
All the analyses were performed according to 
the intention-to-treat principle. Prespecified analy-
ses of the primary outcome were performed in 
six subgroups, as defined by characteristics at 
randomization: age, sex, race, level of respira-
tory support, days since symptom onset, and 
predicted 28-day risk of death. (Details are pro-
vided in the Supplementary Appendix.)
Estimates of rate and risk ratios are shown 
with 95% confidence intervals without adjust-
ment for multiple testing. The P value for the 
assessment of the primary outcome is two-sided. 
The full database is held by the trial team, which 
collected the data from the trial sites and per-
formed the analyses, at the Nuffield Department 
of Population Health at the University of Oxford.
The independent data monitoring committee 
was asked to review unblinded analyses of the 
trial data and any other information that was 
considered to be relevant at intervals of approxi-
mately 2 weeks. The committee was then charged 
with determining whether the randomized com-
parisons in the trial provided evidence with re-
spect to mortality that was strong enough (with 
a range of uncertainty around the results that was 
narrow enough) to affect national and global 
treatment strategies. In such a circumstance, the 
committee would inform the members of the trial 
steering committee, who would make the results 
available to the public and amend the trial ac-
cordingly. Unless that happened, the steering 
committee, investigators, and all others involved 
in the trial would remain unaware of the interim 
results until 28 days after the last patient had 
been randomly assigned to a particular treatment 
group.
On June 4, 2020, in response to a request 
from the MHRA, the independent data monitor-
ing committee conducted a review of the data 
and recommended that the chief investigators 
review the unblinded data for the hydroxychloro-
quine group. The chief investigators and steer-
ing committee members concluded that the data 
showed no beneficial effect of hydroxychloro-
quine in patients hospitalized with Covid-19. 
Therefore, the enrollment of patients in the hy-
droxychloroquine group was closed on June 5, 
2020, and the preliminary result for the primary 
outcome was made public. Investigators were 
advised that any patients who were receiving 




From March 25 to June 5, 2020, a total of 11,197 
patients underwent randomization; of these pa-
tients, 7513 (67%) were eligible to receive hy-
droxychloroquine (i.e., the patient had no known 
indication for or contraindication to hydroxy-
chloroquine, and the drug was available in the 
hospital at the time) (Fig. 1). Of the eligible pa-
tients, 1561 were assigned to receive hydroxy-
chloroquine and 3155 were assigned to receive 
usual care; the remainder of the patients were 
randomly assigned to one of the other treatment 
groups.
The mean (±SD) age of the patients in this 
trial was 65.4±15.3 years (Table 1 and Table S1 
in the Supplementary Appendix). A total of 38% 
of the patients were female; 18% were Black or 
Asian or had a minority ethnic background. No 
children were enrolled. A history of diabetes was 
present in 27% of patients, heart disease in 26%, 
and chronic lung disease in 22%, with 57% hav-
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ing at least one major coexisting illness that was 
recorded. In this analysis, 90% of the patients 
had laboratory-confirmed SARS-CoV-2 infection, 
with the result not known for less than 1%. At 
randomization, 17% were receiving invasive me-
chanical ventilation including extracorporeal 
membrane oxygenation, 60% were receiving oxy-
gen only (with or without noninvasive ventila-
tion), and 24% were receiving neither.
A total of 1430 patients in the hydroxychloro-
quine group (92%) received at least one dose 
(Table S2). The median duration of treatment 
was 6 days (interquartile range, 3 to 10 days). In 
addition, 12 patients (0.4%) in the usual-care 
group received hydroxychloroquine. The frequen-
cy of use of azithromycin or other macrolide 
drug during the follow-up period was similar in 
the hydroxychloroquine group and the usual-
care group (18.6% vs. 20.3%), as was the use of 
dexamethasone (9.1% vs. 9.2%). Remdesivir was 
administered to less than 0.1% of the patients in 
each group.
Primary Outcome
Death at 28 days occurred in 421 of 1561 pa-
tients (27.0%) in the hydroxychloroquine group 
and in 790 of 3155 patients (25.0%) in the usual-
care group (rate ratio, 1.09; 95% confidence in-
terval [CI], 0.97 to 1.23; P = 0.15) (Fig. 2). Similar 
results were seen across all six prespecified sub-
groups (Fig. 3). In a post hoc exploratory analysis 
that was restricted to the 4266 patients (90.5%) 
with a positive SARS-CoV-2 test result, the result 
was similar to the overall result (rate ratio, 1.09; 
95% CI, 0.96 to 1.23).
Secondary Outcomes
Patients in the hydroxychloroquine group had a 
longer duration of hospitalization than those in 
the usual-care group (median, 16 days vs. 13 days) 
and a lower probability of discharge alive within 
28 days (59.6% vs. 62.9%; rate ratio, 0.90; 95% 
CI, 0.83 to 0.98) (Table 2). Among the patients 
Figure 1. Enrollment and Outcomes in the RECOVERY 
Trial.
The enrollment number that is shown is the total num-
ber of patients in the RECOVERY platform trial during 
the period in which adult patients could be recruited 
for the comparison between hydroxychloroquine and 
usual care. Patients could have more than one reason 
for not participating in the hydroxychloroquine trial. At 
the time of this analysis, data from the trial follow-up 
form were available for 1553 of 1561 patients (99.5%) 
in the hydroxychloroquine group and for 3140 of 3155 
patients (99.5%) in the usual-care group. The subgroup 
of patients who later underwent a second randomiza-
tion to tocilizumab versus usual care in the RECOVERY 
trial included 37 of 1561 patients (2.4%) in the hydroxy-
chloroquine group and 89 of 3155 patients (2.8%) in 
the usual care group. In addition, 6 patients were ran-
domly assigned to receive either convalescent plasma 
or usual care alone (1 patient [0.1%] in the hydroxy-
chloroquine group and 5 patients [0.2%] in the usual-
care group) in accordance with protocol version 6.0. 
Among the 167 sites at which at least 1 patient was 
 assigned to receive hydroxychloroquine, the median 
number of patients who underwent randomization  
was 20 (interquartile range, 11 to 41).
7513 (67%) Underwent randomization to receive
hydroxychloroquine or other treatments
11,197 Patients were recruited
639 (6%) Did not have access 
to hydroxychloroquine at their
hospital 
3199 (29%) Were considered 
unsuitable for receiving 
hydroxychloroquine
4716 (42%) Underwent randomization to receive
hydroxychloroquine or usual care alone
2797 Were assigned to another
active treatment
1010 Were assigned to lopinavir–
ritonavir
1170 Were assigned to dexameth-
asone
617 Were assigned to azithro-
mycin
1561 (100%) Were assigned to receive
hydroxychloroquine
1430 of 1553 (92%) Received
hydroxychloroquine
3155 (100%) Were assigned to receive
usual care
12 of 3140 (0.4%) Received 
hydroxychloroquine
3 (0.2%) Withdrew consent 5 (0.2%) Withdrew consent
75 (4.8%) Proceeded to second
randomization
178 (5.6%) Proceeded to second
randomization
1561 (100%) Were included in the
28-day intention-to-treat analysis
3155 (100%) Were included in the
28-day intention-to-treat analysis
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who were not undergoing invasive mechanical 
ventilation at baseline, the number of patients 
who had progression to the prespecified com-
posite secondary outcome of invasive mechani-
cal ventilation or death was higher among those 
in the hydroxychloroquine group than among 







Mean ±SD 65.2±15.2 65.4±15.4
Distribution — no. (%)
<70 yr 925 (59.3) 1873 (59.4)
≥70 to <80 yr 342 (21.9) 630 (20.0)
≥80 yr 294 (18.8) 652 (20.7)
Sex — no. (%)
Male 960 (61.5) 1974 (62.6)
Female† 601 (38.5) 1181 (37.4)
Race or ethnic group — no. (%)‡
White 1181 (75.7) 2298 (72.8)
Black, Asian, or minority ethnic group 264 (16.9) 593 (18.8)
Unknown 116 (7.4) 264 (8.4)
Median no. of days since symptom onset (IQR)§ 9 (5–14) 9 (5–13)
Median no. of days since hospitalization (IQR) 3 (1–6) 3 (1–5)
Respiratory support — no. (%)
No oxygen received 362 (23.2) 750 (23.8)
Oxygen only 938 (60.1) 1873 (59.4)
Invasive mechanical ventilation 261 (16.7) 532 (16.9)
Previous disease — no. (%)
Any of the listed conditions 882 (56.5) 1807 (57.3)
Diabetes 427 (27.4) 856 (27.1)
Heart disease 422 (27.0) 789 (25.0)
Chronic lung disease 334 (21.4) 712 (22.6)
Tuberculosis 4 (0.3) 9 (0.3)
HIV infection 8 (0.5) 13 (0.4)
Severe liver disease¶ 18 (1.2) 46 (1.5)
Severe kidney impairment‖ 111 (7.1) 261 (8.3)
SARS-CoV-2 test result — no. (%)
Positive 1399 (89.6) 2867 (90.9)
Negative 156 (10.0) 275 (8.7)
Unknown 6 (0.4) 13 (0.4)
*  Percentages may not total 100 because of rounding. HIV denotes human immunodeficiency virus, IQR interquartile 
range, and SD standard deviation.
†  Among the women, 2 in the hydroxychloroquine group and 4 in the usual-care group were pregnant.
‡  Race or ethnic group is reported as it was recorded in the patient’s electronic health record.
§  Data regarding the number of days since symptom onset were missing for 9 patients in the hydroxychloroquine group 
and 9 patients in the usual-care group.
¶  Severe liver disease was defined as a diagnosis that resulted in ongoing specialist care.
‖  Severe kidney impairment was defined as an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 
m2 of body-surface area.
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those in the usual-care group (risk ratio, 1.14; 
95% CI, 1.03 to 1.27).
Other Prespecified Outcomes
There was no difference between the hydroxy-
chloroquine group and the usual-care group in 
28-day mortality that was ascribed to Covid-19 
(24.0% vs. 23.5%). However, patients in the hy-
droxychloroquine group had a greater risk of 
death from cardiac causes (mean [±SE] excess, 
0.4±0.2 percentage points) and from non–SARS-
CoV-2 infection (mean excess, 0.4±0.2 percent-
age points) (Table S3). Data regarding the occur-
rence of new major cardiac arrhythmia were 
collected for 735 of 1561 patients (47.1%) in the 
hydroxychloroquine group and 1421 of 3155 pa-
tients (45.0%) in the usual-care group, after col-
lection of this information was added to the 
follow-up form on May 12, 2020. Among these 
patients, there were no significant differences 
between the hydroxychloroquine group and the 
usual-care group in the frequency of supraven-
tricular tachycardia (7.6% vs. 6.0%), ventricular 
tachycardia or fibrillation (0.7% vs. 0.4%), or 
atrioventricular block requiring intervention 
(0.1% vs. 0.1%) (Table S4). There was one report 
of a serious adverse reaction that was deemed by 
investigators to be related to hydroxychloro-
quine: a case of torsades de pointes, from which 
the patient recovered without undergoing inter-
vention. Among the patients who were not re-
ceiving renal dialysis or hemofiltration at ran-
domization, the percentage who went on to 
receive such treatment during the follow-up 
period was the same in the hydroxychloroquine 
group and the usual-care group (7.9% vs. 7.9%) 
(Table S5).
Discussion
In this analysis of the RECOVERY trial, we de-
termined that hydroxychloroquine was not an 
effective treatment for patients hospitalized with 
Covid-19. The lower boundary of the confidence 
limit for the primary outcome ruled out any 
reasonable possibility of a meaningful mortality 
benefit. The results were consistent across sub-
groups according to age, sex, race, time since 
illness onset, level of respiratory support, and 
baseline-predicted risk. In addition, the results 
suggest that the patients who received hydroxy-
chloroquine had a longer duration of hospital-
ization and, among those who were not under-
going mechanical ventilation at baseline, a higher 
risk of invasive mechanical ventilation or death 
than those who received usual care.
The RECOVERY trial is a large, pragmatic, 
randomized, controlled platform trial designed 
to assess the effect of potential treatments for 
Covid-19 on 28-day mortality. Approximately 
15% of the patients who were hospitalized with 
Covid-19 in the United Kingdom during the trial 
period were enrolled, and the percentage of pa-
tients in the usual-care group who died was 
consistent with the hospitalized case fatality rate 
among hospitalized patients in the United King-
dom and elsewhere.7,30,31 Only essential data were 
collected at hospital sites, with additional infor-
mation (including long-term mortality) ascer-
tained through linkage with routine data sources. 
We did not collect information on physiologic, 
electrocardiographic, laboratory, or virologic 
measurements.
Hydroxychloroquine has been proposed as a 
treatment for Covid-19 largely on the basis of its 
Figure 2. Mortality at 28 Days.
Death at 28 days (the primary outcome) occurred in 421 patients (27.0%) 
in the hydroxychloroquine group and in 790 (25.0%) in the usual-care 
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Figure 3. Mortality at 28 Days, According to Subgroup.
The size of the squares representing rate ratios is proportional to the amount of statistical information that was 
available for each comparison. The method that was used for calculating the baseline-predicted risk in each sub-
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335/1181 (28.4) 610/2298 (26.5) 1.09 (0.95–1.25)
65/264 (24.6) 115/593 (19.4) 1.32 (0.96–1.81)
177/622 (28.5) 339/1275 (26.6) 1.10 (0.91−1.32) 
242/930 (26.0) 445/1871 (23.8) 1.11 (0.94−1.30) 
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Rate or Risk Ratio 
(95% CI)
no./total no. (%)
Primary outcome: 28-day mortality 421/1561 (27.0) 790/3155 (25.0) 1.09 (0.97–1.23)*
Secondary outcomes
Discharge from hospital in ≤28 days 931/1561 (59.6) 1983/3155 (62.9) 0.90 (0.83–0.98)*
Invasive mechanical ventilation or death† 399/1300 (30.7) 705/2623 (26.9) 1.14 (1.03–1.27)‡
Invasive mechanical ventilation 128/1300 (9.8) 225/2623 (8.6) 1.15 (0.93–1.41)
Death 311/1300 (23.9) 574/2623 (21.9) 1.09 (0.97–1.23)
*  The between-group difference was calculated as a rate ratio.
†  Patients who were receiving invasive mechanical ventilation at randomization were excluded from this analysis.
‡  The between-group difference was calculated as a risk ratio.
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in vitro SARS-CoV-2 antiviral activity and on data 
from observational studies reporting effective 
reduction in viral loads. However, the 4-amino-
quinoline drugs are relatively weak antiviral 
agents.15 The demonstration of therapeutic effi-
cacy of hydroxychloroquine in severe Covid-19 
would require rapid attainment of efficacious 
levels of free drug in the blood and respiratory 
epithelium.32 Thus, to provide the greatest chance 
of providing benefit in life-threatening Covid-19, 
the dose regimen in our trial was designed to 
result in rapid attainment and maintenance of 
plasma levels that were as high as safely possi-
ble.15 These levels were predicted to be at the 
upper end of those observed during steady-state 
treatment of rheumatoid arthritis with hydroxy-
chloroquine.33 Our dosing schedule was based 
on pharmacokinetic modeling of hydroxychloro-
quine that referenced a SARS-CoV-2 50% effec-
tive concentration of 0.72 μM, as scaled to 
whole-blood levels and on the assumption that 
cytosolic levels in the respiratory epithelium are 
in dynamic equilibrium with blood levels.8,15,34
The primary concern with short-term, high-
dose 4-aminoquinoline regimens is cardiovas-
cular toxicity. Hydroxychloroquine causes pre-
dictable prolongation of the corrected QT interval 
on electrocardiography, which is exacerbated by 
coadministration with azithromycin, as widely 
prescribed in Covid-19 treatment.16-18 Although 
torsades de pointes has been described, serious 
cardiovascular toxicity has been infrequently re-
ported, despite the high prevalence of cardio-
vascular disease in hospitalized patients, the 
common occurrence of myocarditis in Covid-19, 
and the extensive use of hydroxychloroquine 
and azithromycin together. The exception is a 
Brazilian study that was stopped early because 
of cardiotoxicity. However, in that study, chloro-
quine was administered at a base dose of 600 mg 
twice daily for 10 days, a higher total dose than 
those that were used in other trials, including 
the RECOVERY trial.35,36 Pharmacokinetic mod-
eling in combination with information regarding 
blood levels and mortality from a case series 
involving 302 patients with chloroquine over-
dose predicts that a chloroquine regimen that 
was equivalent to the hydroxychloroquine regi-
men used in our trial should have an acceptable 
safety profile.36 There was a small absolute ex-
cess of cardiac mortality of 0.4 percentage points 
in the hydroxychloroquine group on the basis 
of very few events, but we did not observe ex-
cess mortality in the first 2 days of treatment 
with hydroxychloroquine, the time when early 
effects of dose-dependent toxicity might be ex-
pected. Furthermore, the data presented here 
did not show any excess in ventricular tachycardia 
or ventricular fibrillation in the hydroxychloro-
quine group.
These findings indicate that hydroxychloro-
quine is not an effective treatment for hospital-
ized patients with Covid-19 but do not address 
its use as prophylaxis or in patients with less 
severe SARS-CoV-2 infection managed in the com-
munity. A review of Covid-19 treatment guide-
lines that was produced early in the pandemic 
showed that chloroquine or hydroxychloroquine 
was recommended in China, France, Italy, the 
Netherlands, and South Korea.37 In the United 
States, the use of chloroquine and hydroxychlo-
roquine was permitted in certain hospitalized pa-
tients under an Emergency Use Authorization 
(EUA) of the Food and Drug Administration (FDA). 
A retrospective cohort study involving 1376 pa-
tients with Covid-19 who were admitted to the 
hospital in New York City in March and April 
2020 showed that 59% of the patients received 
hydroxychloroquine.22,38 Since our preliminary re-
sults were made public on June 5, 2020, the FDA 
has revoked the EUA for chloroquine and hydroxy-
chloroquine,39 and the World Health Organiza-
tion (WHO) and the National Institutes of Health 
have ceased trials of its use in hospitalized pa-
tients on the grounds of a lack of benefit. The 
WHO has released preliminary results from the 
SOLIDARITY trial on the effectiveness of hy-
droxychloroquine in hospitalized patients with 
Covid-19 that are consistent with the results from 
the RECOVERY trial.40
The views expressed in this article are those of the authors 
and not necessarily those of the National Health Service (NHS), 
the National Institute for Health Research (NIHR), or the De-
partment of Health and Social Care.
Supported by a grant (MC_PC_19056) to the University 
of Oxford from UK Research and Innovation and the NIHR 
and by core funding provided by NIHR Oxford Biomedical 
Research Centre, Wellcome, the Bill and Melinda Gates Foun-
dation, the Department for International Development, Health 
Data Research UK, the Medical Research Council Population 
Health Research Unit, the NIHR Health Protection Unit in 
Emerging and Zoonotic Infections, and NIHR Clinical Trials 
Unit Support Funding. Tocilizumab was provided free of charge 
for this study by Roche. AbbVie contributed some supplies of 
lopinavir–ritonavir for use in the trial. The hydroxychloroquine 
that was used in the trial was supplied by the NHS.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on November 24, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;21 nejm.org November 19, 2020 2039
Hydroxychloroquine in Patients with Covid-19
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
We thank the thousands of patients who participated in this trial; 
the doctors, nurses, pharmacists, other allied health profession-
als, and research administrators at 176 NHS hospitals across the 
United Kingdom who were assisted by the NIHR Clinical Research 
Network, NHS DigiTrials, Public Health England, the Department 
of Health and Social Care, the Intensive Care National Audit and 
Research Centre, Public Health Scotland, National Records Ser-
vice of Scotland, the Secure Anonymised Information Linkage at 
University of Swansea, and the NHS in England, Scotland, Wales, 
and Northern Ireland; and the members of the independent data 
monitoring committee: Peter Sandercock, Janet Darbyshire, David 
DeMets, Robert Fowler, David Lalloo, Ian Roberts, and Janet Wittes.
Appendix
The authors’ full names and academic degrees are as follows: The RECOVERY Collaborative GroupPeter Horby, F.R.C.P., Marion Mafham, 
M.D., Louise Linsell, D.Phil., Jennifer L. Bell, M.Sc., Natalie Staplin, Ph.D., Jonathan R. Emberson, Ph.D., Martin Wiselka, Ph.D., Andrew 
Ustianowski, Ph.D., Einas Elmahi, M.Phil., Benjamin Prudon, F.R.C.P., Tony Whitehouse, F.R.C.A., Timothy Felton, Ph.D., John Wil-
liams, M.R.C.P., Jakki Faccenda, M.D., Jonathan Underwood, Ph.D., J. Kenneth Baillie, M.D., Ph.D., Lucy C. Chappell, Ph.D., Saul N. 
Faust, F.R.C.P.C.H., Thomas Jaki, Ph.D., Katie Jeffery, Ph.D., Wei Shen Lim, F.R.C.P., Alan Montgomery, Ph.D., Kathryn Rowan, Ph.D., 
Joel Tarning, Ph.D., James A. Watson, D.Phil., Nicholas J. White, F.R.S., Edmund Juszczak, M.Sc., Richard Haynes, D.M., and Martin J. 
Landray, Ph.D.
The affiliations of the members of the writing committee are as follows: the Centre for Tropical Medicine and Global Health, Nuffield 
Department of Medicine (P.H., J.T., J.A.W., N.J.W.), Nuffield Department of Population Health (M.M., L.L., J.L.B., N.S., J.R.E., E.J., 
R.H., M.J.L.), the Medical Research Council (MRC) Population Health Research Unit (N.S., J.R.E., R.H., M.J.L.), University of Oxford, 
the Oxford University Hospitals NHS Foundation Trust (K.J., M.J.L.), and the National Institute for Health Research (NIHR) Oxford 
Biomedical Research Centre (M.J.L.), Oxford, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester (M.W.), 
the Regional Infectious Diseases Unit, North Manchester General Hospital (A.U.), University of Manchester (A.U., T.F.), and Manches-
ter University NHS Foundation Trust (T.F.), Manchester, the Research and Development Department, Northampton General Hospital, 
Northampton (E.E.), the Department of Respiratory Medicine, North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees 
(B.P.), University Hospitals Birmingham NHS Foundation Trust and Institute of Microbiology and Infection, University of Birmingham, 
Birmingham (T.W.), James Cook University Hospital, Middlesbrough (J.W.), North West Anglia NHS Foundation Trust, Peterborough 
(J.F.), the Department of Infectious Diseases, Cardiff and Vale University Health Board, and the Division of Infection and Immunity, 
Cardiff University, Cardiff (J.U.), Roslin Institute, University of Edinburgh, Edinburgh (J.K.B.), the School of Life Course Sciences, 
King’s College London (L.C.C.), and the Intensive Care National Audit and Research Centre (K.R.), London, the NIHR Southampton 
Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of 
Southampton, Southampton (S.N.F.), the Department of Mathematics and Statistics, Lancaster University, Lancaster (T.J.), the MRC 
Biostatistics Unit, University of Cambridge, Cambridge (T.J.), and the Respiratory Medicine Department, Nottingham University Hos-
pitals NHS Trust (W.S.L.), and the School of Medicine, University of Nottingham (A.M., E.J.), Nottingham — all in the United King-
dom; and the Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand 
(J.T., J.A.W., N.J.W.).
References
1. Zhu N, Zhang D, Wang W, et al. A 
novel coronavirus from patients with 
pneumonia in China, 2019. N Engl J Med 
2020; 382: 727-33.
2. Verity R, Okell LC, Dorigatti I, et al. 
Estimates of the severity of coronavirus 
disease 2019: a model-based analysis. 
Lancet Infect Dis 2020; 20: 669-77.
3. Zhou F, Yu T, Du R, et al. Clinical 
course and risk factors for mortality of 
adult inpatients with COVID-19 in Wuhan, 
China: a retrospective cohort study. Lan-
cet 2020; 395: 1054-62.
4. Chen N, Zhou M, Dong X, et al. Epide-
miological and clinical characteristics of 
99 cases of 2019 novel coronavirus pneu-
monia in Wuhan, China: a descriptive 
study. Lancet 2020; 395: 507-13.
5. Cao J, Tu W-J, Cheng W, et al. Clinical 
features and short-term outcomes of 102 
patients with coronavirus disease 2019 in 
Wuhan, China. Clin Infect Dis 2020; 71: 
748-55.
6. Ruan Q, Yang K, Wang W, Jiang L, 
Song J. Clinical predictors of mortality 
due to COVID-19 based on an analysis of 
data of 150 patients from Wuhan, China. 
Intensive Care Med 2020; 46: 846-8.
7. Knight SR, Ho A, Pius R, et al. Risk 
stratification of patients admitted to hos-
pital with covid-19 using the ISARIC WHO 
Clinical Characterisation Protocol: devel-
opment and validation of the 4C Mortality 
Score. BMJ 2020; 370: m3339.
8. Wang M, Cao R, Zhang L, et al. Rem-
desivir and chloroquine effectively inhibit 
the recently emerged novel coronavirus 
(2019-nCoV) in vitro. Cell Res 2020; 30: 
269-71.
9. Lu R, Zhao X, Li J, et al. Genomic 
characterisation and epidemiology of 2019 
novel coronavirus: implications for virus 
origins and receptor binding. Lancet 2020; 
395: 565-74.
10. Vincent MJ, Bergeron E, Benjannet S, 
et al. Chloroquine is a potent inhibitor of 
SARS coronavirus infection and spread. 
Virol J 2005; 2: 69.
11. Zhou P, Yang X-L, Wang X-G, et al. 
A pneumonia outbreak associated with a 
new coronavirus of probable bat origin. 
Nature 2020; 579: 270-3.
12. Keyaerts E, Vijgen L, Maes P, Neyts J, 
Van Ranst M. In vitro inhibition of severe 
acute respiratory syndrome coronavirus 
by chloroquine. Biochem Biophys Res 
Commun 2004; 323: 264-8.
13. Rodrigo C, Fernando SD, Rajapakse S. 
Clinical evidence for repurposing chloro-
quine and hydroxychloroquine as anti-
viral agents: a systematic review. Clin 
Microbiol Infect 2020; 26: 979-87.
14. Fantini J, Chahinian H, Yahi N. Syner-
gistic antiviral effect of hydroxychloro-
quine and azithromycin in combination 
against SARS-CoV-2: what molecular dy-
namics studies of virus-host interactions 
reveal. Int J Antimicrob Agents 2020; 56: 
106020.
15. White NJ, Watson JA, Hoglund RM, 
Chan XHS, Cheah PY, Tarning J. COVID-19 
prevention and treatment: a critical analy-
sis of chloroquine and hydroxychloroquine 
clinical pharmacology. PLoS Med 2020; 
17(9): e1003252.
16. Rosenke K, Jarvis MA, Feldmann F, 
et al. Hydroxychloroquine proves ineffec-
tive in hamsters and macaques infected 
with SARS-CoV-2. June 11, 2020 (https://
www . biorxiv . org/ content/ 10 . 1101/ 2020 . 06 
. 10 . 145144v1). preprint.
17. Gautret P, Lagier J-C, Parola P, et al. 
Hydroxychloroquine and azithromycin as 
a treatment of COVID-19: results of an 
open-label non-randomized clinical trial. 
Int J Antimicrob Agents 2020; 56: 105949.
18. Gautret P, Lagier J-C, Parola P, et al. 
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on November 24, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;21 nejm.org November 19, 20202040
Hydroxychloroquine in Patients with Covid-19
Clinical and microbiological effect of a 
combination of hydroxychloroquine and 
azithromycin in 80 COVID-19 patients 
with at least a six-day follow up: a pilot 
observational study. Travel Med Infect Dis 
2020; 34: 101663.
19. Million M, Lagier JC, Gautret P, et al. 
Early treatment of COVID-19 patients 
with hydroxychloroquine and azithromy-
cin: a retrospective analysis of 1061 cases 
in Marseille, France. Travel Med Infect 
Dis 2020; 35: 101738.
20. Gao J, Tian Z, Yang X. Breakthrough: 
chloroquine phosphate has shown appar-
ent efficacy in treatment of COVID-19 
associated pneumonia in clinical studies. 
Biosci Trends 2020; 14: 72-3.
21. Yu B, Li C, Chen P, et al. Low dose of 
hydroxychloroquine reduces fatality of criti-
cally ill patients with COVID-19. Sci China 
Life Sci 2020 May 15 (Epub ahead of print).
22. Geleris J, Sun Y, Platt J, et al. Observa-
tional study of hydroxychloroquine in hos-
pitalized patients with Covid-19. N Engl J 
Med 2020; 382: 2411-8.
23. Mahévas M, Tran V-T, Roumier M, 
et al. Clinical efficacy of hydroxychloro-
quine in patients with covid-19 pneumo-
nia who require oxygen: observational 
comparative study using routine care data. 
BMJ 2020; 369: m1844.
24. Molina JM, Delaugerre C, Le Goff J, 
et al. No evidence of rapid antiviral clear-
ance or clinical benefit with the combina-
tion of hydroxychloroquine and azithro-
mycin in patients with severe COVID-19 
infection. Med Mal Infect 2020; 50: 384.
25. Tang W, Cao Z, Han M, et al. Hydroxy-
chloroquine in patients with mainly mild 
to moderate coronavirus disease 2019: 
open label, randomised controlled trial. 
BMJ 2020; 369: m1849.
26. Huang M, Tang T, Pang P, et al. Treat-
ing COVID-19 with chloroquine. J Mol 
Cell Biol 2020; 12: 322-5.
27. Chen J, Liu D, Liu L, et al. A pilot study 
of hydroxychloroquine in treatment of pa-
tients with moderate COVID-19. Zhejiang 
Da Xue Xue Bao Yi Xue Ban 2020; 49: 215-9. 
(In Chinese.)
28. Chen Z, Hu J, Zhang Z, et al. Efficacy 
of hydroxychloroquine in patients with 
COVID-19: results of a randomized clinical 
trial. April 10, 2020 (https://www . medrxiv 
. org/ content/ 10 . 1101/ 2020 . 03 . 22 
. 20040758v3). preprint.
29. Cavalcanti AB, Zampieri FG, Rosa RG, 
et al. Hydroxychloroquine with or without 
azithromycin in mild-to-moderate Cov-
id-19. N Engl J Med 2020; 383:2041-52.
30. Mekonnen Abate S, Ahmed Ali S, 
Mantfardo B, Basu B. Rate of intensive 
care unit admission and outcomes among 
patients with coronavirus: a systematic 
review and meta-analysis. PLoS One 2020; 
15(7): e0235653.
31. Armstrong RA, Kane AD, Cook TM. 
Outcomes from intensive care in patients 
with COVID-19: a systematic review and 
meta-analysis of observational studies. 
Anaesthesia 2020; 75: 1340-9.
32. Austin D, Okour M. Evaluation of po-
tential therapeutic options for COVID-19. 
J Clin Pharmacol 2020; 60: 976-7.
33. Carmichael SJ, Charles B, Tett SE. 
Population pharmacokinetics of hydroxy-
chloroquine in patients with rheumatoid 
arthritis. Ther Drug Monit 2003; 25: 671-81.
34. Yao X, Ye F, Zhang M, et al. In vitro 
antiviral activity and projection of opti-
mized dosing design of hydroxychloro-
quine for the treatment of severe acute 
respiratory syndrome coronavirus 2 (SARS-
CoV-2). Clin Infect Dis 2020; 71: 732-9.
35. Borba MGS, Val FFA, Sampaio VS, et al. 
Effect of high vs low doses of chloroquine 
diphosphate as adjunctive therapy for pa-
tients hospitalized with severe acute re-
spiratory syndrome coronavirus 2 (SARS-
CoV-2) infection: a randomized clinical 
trial. JAMA Netw Open 2020; 3(4): e208857.
36. Watson JA, Tarning J, Hoglund RM, 
et al. Concentration-dependent mortality 
of chloroquine in overdose. Elife 2020; 9: 
e58631.
37. Dagens A, Sigfrid L, Cai E, et al. 
Scope, quality, and inclusivity of clinical 
guidelines produced early in the covid-19 
pandemic: rapid review. BMJ 2020; 369: 
m1936.
38. Lenzer J. Covid-19: US gives emer-
gency approval to hydroxychloroquine 
despite lack of evidence. BMJ 2020; 369: 
m1335.
39. Letter from the U.S. Food and Drug 
Administration re: revocation of the Emer-
gency Use Authorization (EUA) letter of 
March 20, 2020. June 15, 2020 (https://
www . fda . gov/ media/ 138945/ download).
40. World Health Organization. WHO dis-
continues hydroxychloroquine and lopina-
vir/ritonavir treatment arms for COVID-19. 
July 4, 2020 (https://www . who . int/ news 
- room/ detail/ 04 - 07 - 2020 - who - discontinues 
- hydroxychloroquine - and - lopinavir 
- ritonavir - treatment - arms - for - covid - 19).
Copyright © 2020 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on November 24, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
